Recite me link

1. Within your trust how many intra-vitreal injections/implants of each of the following drugs have been used in the four-month period from May-August 2020:
a. Aflibercept
b. Bevacizumab
c. Brolucizumab
d. Dexamethasone
e. Fluocinolone
f. Ranibizumab
2. If your trust is able to identify intra-vitreal injections/implants by eye condition, please provide the number of injections/implants used from May-August 2020, for each of the following conditions:
Wet Age Related Macular Degeneration (wAMD)
a. Aflibercept
b. Bevacizumab
c. Brolucizumab
d. Dexamethasone
e. Fluocinolone
f. Ranibizumab
Diabetic Macular Oedema (DMO)
a. Aflibercept
b. Bevacizumab
c. Dexamethasone
d. Fluocinolone
e. Ranibizumab
Retinal Vein Occlusion – Central (CRVO) or Branch (BRVO)
a. Aflibercept
b. Bevacizumab
c. Dexamethasone
d. Fluocinolone
e. Ranibizumab
Visual impairment due to choroidal neovascularization secondary to pathologic myopia (mCNV)
a. Aflibercept
b. Bevacizumab
c. Dexamethasone
d. Fluocinolone
e. Ranibizumab
3. Within your trust how many patients have been treated for Uveitis in the four-month period from May to August 2020 with the following?
a. Dexamethasone intra-vitreal implants
b. Any other anti-VEGF injections/implants
c. Infliximab
d. Adalimumab
e. Tocilizumab

Download response Intra-vitreal injections or implants. 101120